drugset / Trial / NCT06996236

Brimonidine Eye Drops in the Prevention of Myopia Progression

NCT06996236

NaSingle-groupOpen-labelPrevention

Summary

Study to determine the efficacy of alpha-2 adrenergic drugs (brimonidine) in the prevention of myopia progression. Given that the drugs used so far have limited efficacy and side effects (loss of near vision, photophobia), it may be an interesting contribution to such treatment at low cost, and to avoid the expense of managing the complications of myopia that develop throughout life.

Timeline

Start
2025-07
Primary completion
2026-07
Completion
2027-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Brimonidine Small molecule 0.025 % Topical

Indications